Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glial cells missing transcription factor 1 (GCM1) is a DNA-binding transcription factor that is essential for the proper formation and differentiation of specific trophoblast subtypes in the human placenta, mainly syncytiotrophoblast and extravillous trophoblast[1][3][4][5]. GCM1 acts primarily as a master regulator of placental development, controlling a critical balance between cytotrophoblast proliferation and differentiation needed for successful pregnancy and fetal growth. Disruption of GCM1 function leads to impaired placentation, causing pregnancy complications such as preeclampsia and intrauterine growth restriction. GCM1 mediates its functions by binding to a unique DNA recognition site (the GCM-motif) and regulating the expression of key downstream genes, including those involved in trophoblast cell fusion and invasiveness[1][3][5]. It is highly specific to trophoblast cells and is evolutionarily conserved from Drosophila, where the gene was originally described, to humans. GCM1 is not currently considered a direct therapeutic target nor is it targeted by existing drugs[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glial cells missing transcription factor 1 (GCM1).